Covance expands global biologics capabilities

Covance, a global drug development services companies, is to expand its large molecule bioanalytical space co-located with the company’s central laboratory facility in Indianapolis, Indiana.

The expansion, which is planned to open during the second half of 2014, will double Covance’s large molecule capacity and is expected to add approximately 100 new positions over the next five years.

'Our new biologics solutions will enable us to work in closer collaboration with our clients, providing them with actionable insights to help expedite their large molecule development,' said Deborah Keller, Executive Vice President, R&D Laboratories, Covance. 'Doubling our large molecule capacity and enhancing a leading team with additional dedicated scientific experts with proven success in managing through these complexities will further strengthen our leadership position in a growing market.'

As part of the ongoing investment in biologics, the company also appointed Dr Mike Holsapple as Executive Director of Global Immunotoxicology. He is a Fellow in the Academy of Toxicological Sciences (ATS) and past President of the Society of Toxicology, bringing more than 30 years of experience in this important field.  In conjunction with this appointment, Covance has launched molecule management teams of experienced scientific leaders to work closely with clients to develop and implement tailored solutions for the development of their biologics.